In Vitro Activities of Four Novel Triazoles against Scedosporium spp.
AUTOR(ES)
Carrillo, A. J.
FONTE
American Society for Microbiology
RESUMO
In order to develop new approaches to the treatment of the severe and usually fatal infections caused by Scedosporium spp., the in vitro antifungal activities of four novel triazoles (posaconazole, ravuconazole, voriconazole, and UR-9825) and some current antifungals (amphotericin B, ketoconazole, itraconazole, and nystatin) were determined. The latter group was clearly ineffective against the two species tested. The four new antifungals showed activity against Scedosporium apiospermum, and UR-9825 and voriconazole were active against S. prolificans.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=90619Documentos Relacionados
- In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp.
- In Vitro Pharmacodynamics of Amphotericin B, Itraconazole, and Voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
- In Vitro and In Vivo Activities of Sitafloxacin against Chlamydia spp.
- In vitro activities of new beta-lactam antibiotics against Acinetobacter spp.
- In vitro activities of new macrolides and rifapentine against Brucella spp.
